Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme
Alexandra Sufit, Alisa B. Lee‐Sherick, Deborah DeRyckere, et al.
PLoS ONE (2016) Vol. 11, Iss. 10, pp. e0165107-e0165107
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment
K. Myers, Sarah R. Amend, Kenneth J. Pienta
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 334
TAM family kinases as therapeutic targets at the interface of cancer and immunity
Deborah DeRyckere, Justus M. Huelse, H. Shelton Earp, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 755-779
Closed Access | Times Cited: 46
Targeting Gas6/TAM in cancer cells and tumor microenvironment
Guiling Wu, Zhiqiang Ma, Yicheng Cheng, et al.
Molecular Cancer (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 156
Molecular insights of Gas6/TAM in cancer development and therapy
Guiling Wu, Zhiqiang Ma, Wei Hu, et al.
Cell Death and Disease (2017) Vol. 8, Iss. 3, pp. e2700-e2700
Open Access | Times Cited: 108
MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system
Justus M. Huelse, Diana Fridlyand, Shelton Earp, et al.
Pharmacology & Therapeutics (2020) Vol. 213, pp. 107577-107577
Open Access | Times Cited: 71
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment
Davide Frumento, Giancarlo Grossi, Marta Falesiedi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1398-1398
Open Access | Times Cited: 10
The role of TAM family receptors and ligands in the nervous system: From development to pathobiology
Bridget Shafit‐Zagardo, Ross C. Gruber, Juwen C. DuBois
Pharmacology & Therapeutics (2018) Vol. 188, pp. 97-117
Open Access | Times Cited: 69
Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment
Joselyn Cruz Cruz, Kristen C. Allison, Lauren S. Page, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Early onset senescence and cognitive impairment in a murine model of repeated mTBI
Nicole Schwab, YoungJun Ju, Lili‐Naz Hazrati
Acta Neuropathologica Communications (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 31
Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma
Shariful Islam, Andrew L. Paek, Michael F. Hammer, et al.
Oncotarget (2018) Vol. 9, Iss. 89, pp. 35875-35890
Open Access | Times Cited: 34
Epigallocatechin‐3‐gallate induces telomere shortening and clastogenic damage in glioblastoma cells
Ion Udroiu, Jessica Marinaccio, Antonella Sgura
Environmental and Molecular Mutagenesis (2019) Vol. 60, Iss. 8, pp. 683-692
Closed Access | Times Cited: 33
Targeting the receptor tyrosine kinase MerTK shows therapeutic value in gastric adenocarcinoma
Naita M. Wirsik, Mingyi Chen, Liping He, et al.
Cancer Medicine (2024) Vol. 13, Iss. 7
Open Access | Times Cited: 3
MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type EGFR Family Members
Dan Yan, Rebecca E. Parker, Xiaodong Wang, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 24, pp. 6523-6535
Open Access | Times Cited: 29
Targeting Options of Tumor-Associated Macrophages (TAM) Activity in Gliomas
Filippos Anagnostakis, Christina Piperi
Current Neuropharmacology (2022) Vol. 21, Iss. 3, pp. 457-470
Open Access | Times Cited: 16
Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
Lenka Sinik, Katherine A. Minson, John J. Tentler, et al.
Molecular Cancer Therapeutics (2018) Vol. 18, Iss. 2, pp. 278-288
Open Access | Times Cited: 27
MERTK Inhibition as a Targeted Novel Cancer Therapy
K.M. Tanim, Alisha Holtzhausen, Aashis Thapa, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7660-7660
Open Access | Times Cited: 2
Modulation of protein S and growth arrest specific 6 protein signaling inhibits pancreatic cancer cell survival and proliferation
Vijaya S. Pilli, Arani Datta, Adrianne W. Dorsey, et al.
Oncology Reports (2020)
Open Access | Times Cited: 18
Immuno-oncology: are TAM receptors in glioblastoma friends or foes?
Yunxiang Zhou, Yali Wang, Hailong Chen, et al.
Cell Communication and Signaling (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 14
Functions of TAM Receptors and Ligands Protein S and Gas6 in Atherosclerosis and Cardiovascular Disease
Teagan Prouse, Samarpan Majumder, Rinku Majumder
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 12736-12736
Open Access | Times Cited: 1
Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma
Kseniya Glinkina, Fariba Némati, Amina F.A.S. Teunisse, et al.
Investigative Ophthalmology & Visual Science (2022) Vol. 63, Iss. 13, pp. 14-14
Open Access | Times Cited: 5
The TAM family as a therapeutic target in combination with radiation therapy
Garth W. Tormoen, Marka R. Crittenden, Michael J. Gough
Emerging Topics in Life Sciences (2017) Vol. 1, Iss. 5, pp. 493-500
Open Access | Times Cited: 7
Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8+ T Cells
Richard Powell, Marlies J. W. Peeters, Anne Rahbech, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1294-1294
Open Access | Times Cited: 6
MERTK Is a Potential Therapeutic Target in Ewing Sarcoma
Sherri K. Smart, Tsz Y. Yeung, M. Olivia Santos, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2831-2831
Open Access
MerTK activity is not necessary for the proliferation of glioblastoma stem cells
Monira Hoque, Siu Wai Wong, Ariadna Recasens, et al.
Biochemical Pharmacology (2021) Vol. 186, pp. 114437-114437
Closed Access | Times Cited: 3
Roles for AXL and MERTK in Resistance to Cytotoxic and Targeted Therapies
Ryan J. Summers, Katherine A. Minson, Deborah DeRyckere, et al.
Elsevier eBooks (2018), pp. 61-85
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top